iMStrong: Deployment of a Biosensor System to Detect Cocaine Use
Biosensor systems are increasingly promoted for use in behavioral interventions. Portable biosensors might offer advancement over self-report use and can provide improved opportunity for detection and intervention in patients undergoing drug treatment programs. Fifteen participants wore a biosensor wristband capable of detecting multiple physiologic markers of sympathetic nervous system (SNS) arousal for 30 days. Urine drug screening and drug use self-report were obtained twice per week. A parameter trajectory description method was applied to capture abrupt changes in magnitude of three measures of SNS activity: Electrodermal activity (EDA), skin temperature and motion. Drug use events detected by the biosensor were verified using a triad of parameters: the biosensor data, urine drug screens, and patient self-report of substance use. Twelve positive cocaine urine screens were identified. Thirteen self-reported episodes of cocaine use were recorded. Distinct episodes with biometric parameters consistent with cocaine use were identified on biosensor data. Eleven potential cocaine use episodes were identified by biosensors that were missed by both self-report and drug screening. Study participants found mobile biosensors to be acceptable, and compliance with the protocol was high. Episodes of cocaine use, as measured by supraphysiologic changes in biophysiometric parameters, were detected by analysis of biosensor data in instances when self-report or drug screening or both failed. Biosensors have substantial potential in detecting substance abuse, in understanding the context of use in real time, and in evaluating the efficacy of behavioral interventions for drug abuse.
KeywordsMobile biosensing Drug abuse mHealth Biosensor system Parameter trajectory
This project was funded by National Institute on Drug Abuse, National Institute of Health (NIH) grants R01DA033769-01, 1R01DA033323-01, and NIH National Center for Advancing Translational Sciences 5UL1TR000161-04 pilot study award.
- 1.Boyer, E. W., Smelson, D., Fletcher, R., Ziedonis, D., and Picard, R. W., Wireless technologies, ubiquitous computing and mobile health: Application to drug abuse treatment and compliance with HIV therapies. J. Med. Toxicol. 6(2):212–216, 2010. doi: 10.1007/s13181-010-0080-z.PubMedCentralCrossRefPubMedGoogle Scholar
- 3.Fletcher, R. R., Tam, S., Omojola, O., Redemske, R., and Kwan, J., Wearable sensor platform and mobile application for use in cognitive behavioral therapy for drug addiction and PTSD. 1–4, 2011.Google Scholar
- 8.Kampman, K. M., New medications for the treatment of cocaine dependence. Psychiatry (Edgmont), 2005.Google Scholar
- 11.Picard, R. W., Fedor, S., and Ayzenberg, Y., Multiple arousal theory and daily-life electrodermal activity asymmetry. Emot. Rev., 2014.Google Scholar
- 13.Poh, M.-Z., Swenson, N. C., and Picard, R. W., A wearable sensor for unobtrusive, long-term assessment of electrodermal activity. IEEE Trans. Biomed. Eng. 57(5):1243–1252. doi: 10.1109/TBME.2009.2038487.
- 14.Carreiro, S., Smelson, D., Ranney, M., et al., Real-time mobile detection of drug use with wearable biosensors: A pilot study. J. Med. Toxicol. 1–7, 2014. doi: 10.1007/s13181-014-0439-7.